Thanks for your comments @Phaedrus and @dachopper.
Since the ARDS trial, I have been curious as to whether Remestemcel-L combined with corticosteroids may exhibit the same synergistic effects that were observed in the ARDS trial in other indications such as AGvHD.
Steroids will be cheaper as a first-line therapy. However, as we gain more insight regarding mechanism of action and the characteristics that identify patients who are likely to benefit from Rem-L (e.g. high MAP scores, inflammatory biomarkers), it seems quite plausible that doctors could prescribe it as a first-line therapy for those target population - particularly in severe cases. This paper provides a nice summary of recent progress that has been made to identify metrics for stratification of patients for MSC therapies: https://www.sciencedirect.com/science/article/pii/S1465324923010496
2024 Here we go again., page-524
-
- There are more pages in this discussion • 420 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.04 |
Change
0.060(6.15%) |
Mkt cap ! $1.181B | |||
| Open | High | Low | Value | Volume |
| 97.0¢ | $1.04 | 96.0¢ | $6.538M | 6.424M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9000 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 118502 | 6 |
View Market Depth
| Last trade - 16.10pm 20/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |